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ABSTRACT
Ether lipids, such as plasmalogens, are peroxisome-
derived glycerophospholipids in which the hydrocarbon
chain at the sn-1 position of the glycerol backbone is
attached by an ether bond, as opposed to an ester bond
in the more common diacyl phospholipids. This seem-
ingly simple biochemical change has profound struc-
tural and functional implications. Notably, the tendency
of ether lipids to form non-lamellar inverted hexagonal
structures in model membranes suggests that they have
a role in facilitating membrane fusion processes. Ether
lipids are also important for the organization and sta-
bility of lipid raft microdomains, cholesterol-rich mem-
brane regions involved in cellular signaling. In addition
to their structural roles, a subset of ether lipids are
thought to function as endogenous antioxidants, and
emerging studies suggest that they are involved in cell
differentiation and signaling pathways. Here, we review
the biology of ether lipids and their potential signiﬁ-
cance in human disorders, including neurological dis-
eases, cancer, and metabolic disorders.
KEYWORDS ether lipids, plasmalogen, phospholipid,
peroxisomes, cancer, metabolic disorders
INTRODUCTION
Conventional glycerophospholipids have acyl chains
attached to the sn-1 and sn-2 positions of the glycerol
backbone by ester bonds. Ether lipids are a unique class of
glycerophospholipids that have an alkyl chain attached to
the sn-1 position by an ether bond (Fig. 1). The alcohol
moiety attached to the phosphate group in ether lipids is
generally choline or ethanolamine, but occasionally inositol
or serine have also been observed. Ether lipids constitute
approximately 20% of the total phospholipid pool in mam-
mals, but tissue distribution varies. The highest levels are
found in the brain, heart, spleen, and white blood cells, while
liver has scant amount of intracellular ether lipids (Braver-
man and Moser, 2012).
Plasmalogens are the most common form of ether lipids
and are characterized by a cis double bond adjacent to the
ether linkage. Plasmalogens were serendipitously discov-
ered in 1924 by Feulgen and Voit while staining tissue sec-
tions with a nuclear stain that reacts with aldehydes released
by acid hydrolysis of DNA (Snyder, 1999). Because the acid
treatment also resulted in breakdown of the vinyl ether bond
of plasmalogens to generate aldehydes, the researchers
unexpectedly also observed cytoplasmic staining and
named the unknown source of aldehydes “plasmalogens”.
The study of plasmalogens and ether lipids in general has
been long and arduous and in the beginning the progress
was slow and scattered. Recently, much advancement has
been made in our understanding of the roles of ether lipids in
health and disease.
In this review, we outline the pathway of ether lipid
biosynthesis and then describe the unique structural roles
played by ether lipids in mammalian cell membranes, fol-
lowed by a discussion of emerging cellular functions of these
lipids. Lastly, we review the current knowledge of the role of
ether lipid metabolism in disease.
BIOSYNTHESIS OF ETHER LIPIDS
Ether lipids are synthesized through a well-characterized
process that begins in the peroxisome and is completed in
the ER (Fig. 2). The peroxisomal component is referred to as
the acyl-dihydroxyacetone (DHAP) pathway since DHAP, a
glycolysis intermediate, is used as a precursor for ether lipid
synthesis (Hajra and Das, 1996). Fatty acids for ether lipid
synthesis are thought to be derived from fatty acid synthase
(FAS)-mediated de novo lipogenesis or dietary sources
(Lodhi et al., 2012, 2015). FAS, a large multifunctional
enzyme that primarily synthesizes palmitate (C16:0), is
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partially localized to the peroxisomes, where it interacts with
various peroxisomal proteins (Hillebrand et al., 2012; Lodhi
et al., 2012; Cader et al., 2016). In order to be used for ether
lipid synthesis, fatty acids are ﬁrst activated to fatty acyl-
CoAs by an acyl-CoA synthetase (ACS) associated with the
peroxisomal membrane. Glyceronephosphate O-acyltrans-
ferase (GNPAT), a peroxisomal matrix protein, uses a long
chain acyl-CoA to acylate DHAP at the sn-1 position. The
next peroxisomal step is catalyzed by alkylglycerone phos-











































Figure 1. Chemical structures of diacyl and ether-linked phospholipids. Diacyl phospholipids have fatty acyl side chains linked
to the sn-1 and sn-2 position of the glycerol backbone by ester bonds. Ether-linked phospholipids are a subclass of
glycerophospholipids that have an alkyl chain attached by an ether bond at the sn-1 position. The sn-2 position of ether lipids
generally has an ester-linked acyl chain, as in diacyl phospholipids. Some ether-linked phospholipids, called alkenyl-acylphospho-
lipids, contain a cis double bond adjacent to the ether linkage and are commonly referred to as plasmalogens. The polar head group






























































Figure 2. Acyl-DHAP pathway of ether lipid synthesis. This process begins in peroxisomes and is subsequently completed in the
ER. The pathway utilizes dihydroxyacetone phosphate (DHAP) generated by glycerol 3-phosphate dehydrogenase (G3PDH)-
mediated dehydrogenation of G3P as the substrate for ether lipid synthesis. Fatty acid synthase (FAS)-mediated de novo lipogenesis
generates fatty acyl-CoA that is utilized by glyceronephosphate O-acyltransferase (GNPAT) or reduced to a fatty alcohol by a fatty
acyl-CoA reductase (FAR1 or FAR2) to later be catalyzed by alkylglycerone phosphate synthase (AGPS), forming the ether bond and
exchanging the acyl chain for an alkyl group. PexRAP (an acyl/alkyl DHAP reductase) then catalyzes the ﬁnal peroxisomal step,
generating the ether lipid precursors, 1-O-alkyl-G3P (AGP) or the diacyl phospholipid precursor lysophosphatidic acid (LPA). The
completion of phospholipid synthesis occurs in the ER. This includes acylation of the glycerol backbone at the sn-2 position,
converting LPA to diacylglycerol (DAG) and AGP to alkyl-acylglycerol (AAG), as well as addition of a cytidine diphosphate-alcohol
head group (such as CDP-choline or CDP-ethanolamine) at the sn-3 position to form the mature phospholipid.
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ether bond at the sn-1 position by exchanging an acyl chain
for an alkyl group. The alkyl moiety used in the AGPS-cat-
alyzed step is generated by a peroxisomal membrane-as-
sociated fatty acyl-CoA reductase (FAR1 or FAR2), which
reduces an acyl-CoA to a fatty alcohol. The ﬁnal peroxisomal
step in ether lipid synthesis is carried out by acyl/alkyl-DHAP
reductase, which reduces alkyl-DHAP into the ether lipid
precursor 1-O-alkyl glycerol-3-phosphate (AGP). The DHAP
reductase can also reduce acyl-DHAP to generate the diacyl
phospholipid precursor lysophosphatidic acid (LPA) as an
alternative to direct acylation of glycerol-3-phosphate (G3P)
by a G3P acyltransferase (GPAT) (Hajra and Das, 1996).
Further steps to convert AGP or LPA to corresponding ether-
linked or diacyl glycerolipids, such as phosphatidylcholine or
phosphatidylethanolamine, take place in the ER (Hajra and
Das, 1996; Gibellini and Smith, 2010). Tethering of peroxi-
somes to the ER for completion of lipid synthesis was
recently shown to involve interaction of the peroxisomal
protein acyl-CoA-binding domain 5 (ACBD5) with VAMP-
associated proteins A and B (VAPA and VAPB), ER-resident
proteins that recruit organelles to the ER (Hua et al., 2017).
The precise mechanism through which the ACBD5-VAP
complex permits exchange of lipids between the organelles
is unclear.
Although the acyl/alkyl-DHAP reductase protein was
puriﬁed from guinea pig liver and biochemically character-
ized over 40 years ago (LaBelle and Hajra, 1974), the gene
encoding this enzyme in mammals remained unknown. We
recently identiﬁed this gene as dhrs7b and renamed the
protein PexRAP (for peroxisomal reductase activating
PPARγ) based on its proposed function in adipose tissue
(Lodhi et al., 2012). Unlike inactivation of GNPAT (also called
DHAP acyltransferase), which results in almost complete
loss of ether lipids (Rodemer et al., 2003), knockout of
PexRAP in mice results in 50–80% decrease in the ether
lipid levels (Lodhi et al., 2015). Similarly, approximately 50%
decrease in ether lipids was observed in a mutant of CHO-
K1 cells with almost complete absence of acyl/alkyl DHAP
reductase activity isolated in an ethyl methanesulfonate
(EMS) mutagenesis screen (James et al., 1997), suggesting
that there is a salvage pathway of ether lipid synthesis. The
precise nature of this salvage pathway is poorly understood,
but is thought to involve dephosphorylation of alkyl-DHAP to
alkyl-dihydroxyacetone, followed by its reduction to alkyl-
glycerol, which upon phosphorylation can re-enter the
biosynthetic pathway downstream of acyl/alkyl-DHAP
reductase (James et al., 1997).
BIOLOGICAL FUNCTIONS OF ETHER LIPIDS
Ether lipids are chemically distinct from their diacyl coun-
terparts, allowing them to contribute unique structural char-
acteristics to biological membranes, which affect such
factors as membrane ﬂuidity and membrane fusion. In
addition to these effects on membrane dynamics, studies
with in vitro and in vivo models of ether lipid deﬁciency
suggest that ether lipids are involved in a variety of biological
functions, including regulating cell differentiation, impacting
cellular signaling, and reducing oxidative stress through their
ability to function as potential endogenous antioxidants.
Structural roles
Ether lipids are a major structural component of cell mem-
branes. The incorporation of ether-linked alkyl chains in
phospholipids alters their physical properties and affects
membrane dynamics. This is largely attributed to the lack of
a carbonyl oxygen at the sn-1 position, which facilitates
stronger intermolecular hydrogen bonding between the
headgroups (Lohner, 1996). Moreover, the vinyl-ether link-
age of plasmalogens at the sn-1 position allows the proximal
regions of the sn-1 and sn-2 chains to become parallel,
favoring close alignment (Han and Gross, 1990; Paltauf,
1994), therefore permitting tighter packing of phospholipids
in the membrane resulting in decreased membrane ﬂuidity
and increased rigidity. This property is particularly important
in higher order membrane structures such as those found in
myelin, evidenced by its enrichment in plasmalogens (Fa-
rooqui and Horrocks, 2001). Both ether lipid-deﬁcient mouse
models and human patients with ether lipid deﬁciency often
display defects in myelination in both the central and
peripheral nervous systems (da Silva et al., 2012).
Plasmalogens are enriched in lipid raft microdomains
(LRM), cholesterol-rich regions of membranes where many
cellular signaling proteins are concentrated (Pike et al.,
2002; Rodemer et al., 2003). Recently, lipidomic analysis of
rat synaptic membranes during the ﬁrst 60 days of postnatal
development showed dynamic changes in membrane lipids,
including the progressive accumulation of plasmalogens
along with cholesterol and sphingolipids. Reconstitution of
this membrane remodeling in a model membrane system
was associated with enhancement of raft domain stability
(Tulodziecka et al., 2016). Consistent with the requirement of
plasmalogens in the organization of LRM, plasmalogen-de-
ﬁcient GNPAT knockout mice display disrupted lipid raft
formation and mislocalization of cholesterol to a perinuclear
compartment (Rodemer et al., 2003).
Disruption of cellular phospholipid composition affects
membrane integrity (Li et al., 2006), activates ER stress (Fu
et al., 2011; Volmer et al., 2013), and promotes apoptosis
(Yen et al., 1999). It has long been known that ether-linked
phospholipids are abundantly present in neutrophils, con-
stituting nearly half of the phosphatidylcholine pool (Mueller
et al., 1982, 1984; Bräutigam et al., 1996; Nagan and Zoeller,
2001). However, the physiological signiﬁcance of these lipids
in neutrophils has remained unclear. Our recent studies with
genetic inactivation of lipogenesis in mice suggest that ether
lipids are an important membrane component required for
survival of mature neutrophils (Fig. 3). Tamoxifen-inducible
global knockout of FAS results in a preferential decrease in
ether-linked glycerophosphocholines (ether-lipid equivalent
of phosphatidylcholine; GPC) in neutrophils (Lodhi et al.,
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2015), increased ER stress and apoptosis, resulting in nearly
complete neutropenia, suggesting that FAS channels fatty
acids to peroxisomes for lipid synthesis. Indeed, FAS has
been shown to interact with PMP70, an ATP binding cassette
subfamily D transporter that transports fatty acyl CoA into
peroxisomes (Hillebrand et al., 2012), directly linking FAS to
peroxisomal lipid metabolism. Consistent with the impor-
tance of peroxisome-derived lipids in neutrophil survival,
tamoxifen-inducible knockout of PexRAP also results in
neutropenia due to decreased ether lipid levels, recapitulat-
ing the results obtained with FAS knockout (Lodhi et al.,
2015). These results suggest that peroxisome-derived lipids,
including ether lipids, are an important structural component
of neutrophil membranes and reveal a novel lipogenic
pathway that selectively regulates neutrophil development.
Membrane trafﬁcking
Model membranes enriched in plasmalogens have a greater
tendency to form non-lamellar inverse hexagonal structures
at lower temperatures as compared to such membranes
composed of diacyl phospholipids (Glaser and Gross, 1994).
Since a transition from a lamellar (no curvature) to an
inverted hexagonal (negative curvature) phase is required
for membrane fusion (Marrink and Mark, 2004), this property
of plasmalogens has been linked to their role in facilitating
processes of membrane trafﬁcking. Notably, synaptic vesi-
cles are enriched in ether lipids, and neurotransmitter
release from these vesicles into the presynaptic cleft is
impaired in the synaptosomes (nerve terminals) isolated
from the brains of ether lipid deﬁcient mice (Brodde et al.,
2012). In further support of the notion that ether lipids facil-
itate membrane fusion processes, ether lipid deﬁciency
disrupts the integrity of the blood-testis barrier by affecting
the sorting, endocytosis, and recycling of tight junction pro-
teins (Komljenovic et al., 2009). Moreover, plasmalogens
have been implicated in cholesterol transport. CHO cells with
a defect in plasmalogen synthesis have impaired plasma
membrane to ER transport and esteriﬁcation of cholesterol
(Munn, 2003). It is unclear whether plasmalogens directly
regulate cholesterol transport through effects on membrane
dynamics or if a signaling molecule released from hydrolysis
of plasmalogens is involved in the process.
Cell signaling and differentiation
In addition to their structural roles, ether lipids can also act as
biological signaling molecules. Oxidation of the vinyl-ether
bond of plasmalogens by brominating species produced by
an eosinophil peroxidase in activated eosinophils results in a
α-bromo fatty aldehyde that acts as a phagocyte chemoat-
tractant for the recruitment of other leukocytes to sites of
inﬂammation (Thukkani et al., 2002; Albert et al., 2003).
Moreover, ether-linked mono-alkyl glycerophosphates serve
as endogenous antigens to activate invariant natural killer T
(iNKT) cells. GNPAT-deﬁcient mice show impaired thymic
maturation of iNKT cells and have a reduced overall number
of iNKT cells in the thymus and periphery, suggesting that
ether lipids are important for the development of these cells
(Facciotti et al., 2012).
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Figure 3. Peroxisomal lipid synthesis is required for maintaining neutrophil viability and membrane integrity. In healthy
neutrophils, fatty acid synthase (FAS) and PexRAP participate in peroxisomal lipid synthesis, including the generation of ether-linked
phospholipids that are incorporated into the plasma membrane, contributing to membrane integrity. Genetic ablation of FAS or
PexRAP disrupts the lipid synthetic pathway, leading to a preferential loss of ether-linked phospholipids in neutrophils. This alters
membrane stability, leading to the activation of ER stress, increased apoptosis, and ultimately neutropenia.
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Ether lipids have also been identiﬁed as potential
endogenous ligands of peroxisome proliferator-activated
receptor gamma (PPARγ) (Davies et al., 2001; McIntyre
et al., 2003; Zhang et al., 2004; Tsukahara et al., 2006), a
nuclear receptor critical for adipose tissue development and
lipid metabolism, which is the target of the glitazone family of
diabetes drugs. Using an unbiased mass spectrometry-
based approach, we identiﬁed several ether-linked GPC
species that were bound to PPARγ in a rosiglitazone-dis-
placeable manner. Treatment of cells with one of these lipid
species promoted PPARγ-dependent luciferase reporter
activity (Lodhi et al., 2012). Furthermore, inhibition of ether
lipid biosynthesis by knockdown of PexRAP blocks PPARγ
dependent gene expression and adipocyte differentiation.
This effect was rescued by rosiglitazone treatment, sug-
gesting that peroxisomal lipid synthesis is involved in
endogenous ligand generation (Lodhi et al., 2012). Recently,
disruption of peroxisomal biogenesis by Pex16 knockdown
was shown to impair PPARγ activation and adipocyte dif-
ferentiation. The defect in adipogenesis was rescued with
the treatment of alkyl glycerol (Hofer et al., 2017), an ether
lipid precursor that enters the synthetic pathway downstream
of the peroxisomal steps.
Ether lipids have also been implicated in the differentia-
tion of other cell types. In the peripheral nervous system,
Schwann cells are required for maintaining axonal health
and myelination. Impaired ether lipid synthesis is associated
with defects in myelination and myelin structure (Brites,
2003; Rodemer et al., 2003; Teigler et al., 2009). Recent
studies suggest that this may be related to the requirement
of plasmalogens in Schwann cell differentiation and function.
Plasmalogen deﬁciency mediated by GNPAT or Pex7
knockout in mice impairs membrane recruitment and
activation of Akt, resulting in hyperactivation of glycogen
synthase kinase 3β (GSK3β), which inhibits Schwann cell
differentiation (Fig. 4). This in turn impairs axonal sorting and
myelination. Inhibition of GSK3β using lithium rescues Sch-
wann cell differentiation, bypassing the effect of plasmalogen
deﬁciency (da Silva et al., 2014). Plasmalogens have also
been implicated in Akt signaling in other cell types. Plas-
malogens protect against apoptosis induced through serum
starvation by modulating Akt signaling, a pathway possibly
mediated through plasmalogens’ ability to activate G-protein
coupled receptor signaling (Hossain et al., 2013, 2016).
Supplementation of Neuro-2 cells with plasmalogens sup-
press neuronal apoptosis signaling induced via serum star-
vation (Yamashita et al., 2015a).
Plasmalogens as cellular antioxidants
Plasmalogen-deﬁcient cultured cells and animals have long
been known to be more sensitive to oxidative damage as
compared to their wild-type counterparts, setting the basis
for the notion that plasmalogens may function as cellular
antioxidants (Morand et al., 1988; Zoeller et al., 1988; Reiss
et al., 1997). This is thought to be due to the presence of the
vinyl ether bond, which makes plasmalogens susceptible to
oxidative attacks. In particular, there is evidence to suggest
that plasmalogens could protect unsaturated membrane
lipids from oxidation by singlet oxygen (Broniec et al., 2011).
Plasmalogens may also be involved in scavenging a variety
of reactive oxygen species (ROS) (Morand et al., 1988;
Khaselev and Murphy, 1999; Maeba et al., 2002; Skaff et al.,
2008). Recent studies suggest that myelin in sciatic and
optic nerves from plasmalogen-deﬁcient mice lacking the
peroxisomal biogenesis factor Pex7 is signiﬁcantly more













Figure 4. Role of ether lipids in Schwann cell differentiation and myelination. In a healthy Schwann cell, the cell membrane is
enriched in plasmalogens. This is necessary for proper recruitment of Akt to the plasma membrane, resulting in its phosphorylation
and activation. Activated Akt phosphorylates GSK3β at Ser9, inhibiting its activity. Plasmalogen deﬁciency impairs recruitment and
activation of Akt, preventing it ability to inhibit GSK3β. Active GSK3β impairs Schwann cell differentiation, resulting in disrupted radial
sorting and myelination. Supplementation of lithium or TDZD-8 to inhibit GSK3β rescues plasmalogen-deﬁcient phenotype, restoring
differentiation and myelination.
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susceptible to oxidative damage than the myelin from wild-
type mice (Luoma et al., 2015).
The idea that plasmalogens have a protective role against
oxidative damage is difﬁcult to validate directly in complex
biological systems. Paradoxically, pro-oxidant effects of
these lipids have also been reported in a bulk lipid system
(Wang and Wang, 2010). A recent study using synthetic
choline plasmalogens in model membrane systems sug-
gests that the antioxidant effect of plasmalogens occurs
intramolecularly rather than intermolecularly and depends on
the degree of unsaturation of the sn-1 and sn-2 chains, the
length of these chains, and their conformation in membranes
(Broniec et al., 2017). This suggests that the antioxidant
capacity of plasmalogens may be contextually dependent.
ETHER LIPIDS IN DISEASE
The critical importance of ether lipids for health in humans is
highlighted by the severity of inherited peroxisomal disorders
caused by ether lipid deﬁciency. Emerging studies suggest
that altered ether lipid production is also associated with
several other disorders including neurodegenerative dis-
eases, cancer, and metabolic disorders. However, the
molecular mechanisms underlying the role of ether lipids in
these diseases remain unclear for the most part, suggesting
a need for future research.
Genetic peroxisomal disorders resulting in ether lipid
deﬁciency
Rhizomelic chondrodysplasia punctata
Rhizomelic chondrodysplasia punctata (RCDP) is a peroxi-
somal disorder caused by ether lipid deﬁciency. RCDP is a
multisystem, developmental disorder and has a rare occur-
rence affecting approximately 1/100,000 individuals. Symp-
toms include not only those that give the disease its
namesake, shortening of limbs (rhizomelia) and multiple
punctate epiphyseal calciﬁcation (chondrodysplasia punc-
tata), but also microcephaly, distinct facial features, catar-
acts, and psychomotor retardation. The disease is fatal with
patients rarely surviving past the tenth year of life (Braver-
man and Moser, 2012; White et al., 2003). The most com-
mon form is RCDP type 1, which is caused by mutations in
Pex7, a peroxisomal import receptor for proteins, including
AGPS, that contain a type 2 peroxisomal targeting sequence
(PTS), resulting in defects in peroxisomal biogenesis
(Braverman et al., 1997; Motley et al., 1997; Purdue, 1997).
The less common RCDP types 2 and 3 are caused by single
enzyme mutations in either the GNPAT or AGPS genes,
respectively, and result in deﬁcient ether lipid biosynthesis.
Recently, two new types of RCDP have been reported.
RCDP type 4 results from a mutation in FAR1, which is
required for the conversion of fatty acyl-CoAs to fatty alco-
hols (Honsho et al., 2013; Buchert et al., 2014). RCDP type 5
results from a genetic mutation leading to speciﬁc loss of
only the Pex5 long isoform (Pex5L). While both the long and
short Pex5 isoforms recognize PTS1-containing proteins,
Pex5L is a co-receptor with Pex7 for the import of PTS2-
containing proteins, and its loss results only in impaired
PTS2-tagged protein import and RCDP phenotype (Barøy
et al., 2015).
Zellweger spectrum disorders
Peroxisomal biogenesis disorders in the Zellweger spectrum
are a heterogeneous group of genetic disorders encom-
passing Zellweger syndrome, neonatal adrenoleukodystro-
phy, and infantile Refsum disease. They are caused by a
mutation in one of the dozen Pex genes required for normal
assembly and functions of peroxisomes and affect approxi-
mately 1 in 50,000 individuals. Mutations in Pex1 are the
most common, accounting for nearly 70% of cases. How-
ever, mutations in Pex3, Pex16, and Pex19 result in the
complete absence of peroxisomes and are coupled to the
most severe phenotypes (Steinberg et al., 2012). Like
RCDP, Zellweger spectrum disorders (ZSD) present with a
broad range of clinical characteristics, which include cran-
iofacial abnormalities, chondrodysplasia punctata, hep-
atomegaly, kidney abnormalities, and vision problems.
Infants with a severe form of ZSD (Zellweger syndrome)
have multiple developmental abnormalities and generally die
within the ﬁrst year of life. Along with blood accumulation of
very long chain and branched chain fatty acids, which
require peroxisomes for their oxidation, decreased ether lipid
levels in red blood cell membranes are one of the criteria for
diagnosis of ZSD (Braverman et al., 2016).
Generation of mouse models of ether lipid deﬁciency has
shed some light on the pathophysiology of peroxisomal
biogenesis disorders. These mice show defects in neuronal
development and myelination (Brites, 2003; Rodemer et al.,
2003; Teigler et al., 2009). As discussed above, Schwann
cells of ether-lipid deﬁcient mice show impaired differentia-
tion and myelination resulting from decreased Akt signaling,
presumably due to the necessity of plasmalogens for correct
recruitment of Akt to the membrane (da Silva et al., 2014).
Alterations in ether lipid levels in common disease
states
Neurological disorders
Alzheimer’s disease (AD) pathology is associated with
decreased ether lipids, particularly plasmalogens, in the
brain (Ginsberg et al., 1995, 1998; Han et al., 2001; Han,
2005). Additionally, serum levels of ethanolamine plas-
malogens in AD patients are decreased and correlate with
the severity of disease progression (Goodenowe et al., 2007;
Wood et al., 2010). Given this relationship, serum plas-
malogen levels have even been used to successfully stratify
diseased patients (Wood et al., 2016). Increased β-amyloid
(Aβ) levels associated with AD have been shown to promote
Roles of ether lipids REVIEW









oxidative stress in the brain, leading to loss of peroxisomal
function. This in turn decreases AGPS (the rate-limiting
enzyme of ether lipid synthesis) activity, ultimately lowering
plasmalogen levels (Grimm et al., 2011). In addition, certain
ethanolamine plasmalogen species are thought to have the
ability to destabilize existing Aβ ﬁbrils in vitro and prevent the
formation of new ﬁbrils in a dose dependent manner, pro-
viding another mechanism by which plasmalogen loss
facilitates AD pathology (Yamashita et al., 2015b).
Abnormal ether lipid levels have also been implicated in
other neurological disorders. Red blood cells and ﬁbroblasts
collected from schizophrenia patients were recently shown
to be signiﬁcantly decreased in plasmalogen levels (Tessier
et al., 2016; Huang et al., 2016). In addition, patients with
Parkinson’s disease show severe alterations in neuronal
membrane composition, including a signiﬁcant decrease in
postmortem frontal cortex lipid raft plasmalogens levels
(Fabelo et al., 2011). Additional work is needed to under-
stand the molecular mechanism through which reduced
ether lipids contribute to these pathologies.
Cancer
Decades ago it was observed that cancer cells have
remarkably higher levels of ether lipids compared to normal
cells, suggesting that ether lipids may be involved in cancer
pathogenesis (Snyder et al., 1966, 1969; Snyder and Wood,
1969; Albert and Anderson, 1977; Roos and Choppin, 1984).
Indeed, increased ether lipids are correlated with more
aggressive cancers, and knockdown of AGPS in a variety of
cancer cell lines results in impaired pathogenicity (Benjamin
et al., 2013). A small molecule screen identiﬁed an inhibitor
of AGPS that decreases ether lipid levels and appears to
reduce pathogenicity of human cancer cells in vitro (Piano
et al., 2015). Recently, a lipidomics study on breast cancer
patients identiﬁed increased plasma ether-linked phos-
phatidylcholine species as a diagnostic marker for breast
cancer (Chen et al., 2016). It is unclear whether ether lipids
play a structural or signaling role in promoting cancer
progression.
Metabolic disorders
Levels of plasmalogen and other ether-linked phosphatidyl-
choline species are increased in steatotic livers of high fat
diet-fed mice, although it is unclear whether this is due to
increased synthesis, reduced degradation, or impaired
hepatic release (Eisinger et al., 2014). One possibility is that
increased plasmalogens may be an indication of increased
activity of protective mechanisms against oxidative stress
(Barr et al., 2012). However, serum plasmalogen levels are
decreased in patients with nonalcoholic steatohepatitis
(NASH) and nonalcoholic fatty liver disease (NAFLD) as
compared to healthy controls (Puri et al., 2009). This drop in
plasmalogen levels is more severe in NASH patients as
opposed to simple steatosis patients suggesting the possi-
bility to use serum lipidomics as a biomarker to diagnose and
stratify the disease. Recent studies suggest a protective role
of plasmalogens against NASH. Free cholesterol-induced
NASH in mice was associated with decreased levels of
docosahexaenoic acid-containing plasmalogens and
impaired expression of PPARα, a critical transcriptional
regulator of fatty acid oxidation. Rescue of plasmalogen
levels by alkyl glycerol treatment prevented hepatic steatosis
and NASH through PPARα-dependent increase in fatty acid
oxidation, suggesting a role for endogenous plasmalogen
production in PPARα signaling (Jang et al., 2017).
Decreased serum ether lipid levels have been implicated
in hypertension and obesity (Pietiläinen et al., 2007;
Graessler et al., 2009). In a weight-discordant twin study,
obese patients showed a decrease in serum plasmalogens
compared to healthy twin controls, indicating that the effect is
independent of genetic makeup (Pietiläinen et al., 2007).
Similarly, a follow up study by the same group showed that
plasmalogens containing arachidonic acid at the sn-2 posi-
tion are reduced in the adipocyte membranes of morbidly
obese twins compared to metabolically healthy twins (Pi-
etiläinen et al., 2011). Conversely, serum plasmalogen levels
increase in men with aerobic training and in patients with a
healthy dietary intervention (Lankinen et al., 2016; Felder
et al., 2017).
Altered ether lipid levels are also associated with type 1
diabetes (T1D). Interestingly, decreased ether lipids were
detected in the serum of children that were later diagnosed
with T1D. The presence of these metabolic changes prior to
the detection of autoantibodies suggests that ether lipid
metabolism is dysregulated before the disease emerges
(Orešič et al., 2008). It is unresolved whether the decreased
ether lipid levels contribute to accelerating pathology of
diabetes or are related to secondary metabolic changes.
However, β cells are known to possess inherently poor
antioxidant capacity (Lenzen et al., 1996), and this coupled
with the lower levels of plasmalogens may result in
enhanced susceptibility of β cells to metabolic stress and
ROS contributing to the autoimmune response. Regardless
of the mechanism, changes in lipid metabolism may serve as
useful markers for early diagnosis.
CONCLUDING REMARKS AND FUTURE
DIRECTIONS
With the rising interest in lipidomics, ether lipids have
emerged as potential biomarkers of several diseases,
including neurodegenerative diseases, cancer, and meta-
bolic disorders (Eisinger et al., 2014; Chen et al., 2016;
Tessier et al., 2016; Alshehry et al., 2016). However, with this
observation comes the principal question: Are the changes
in ether lipid levels merely a byproduct of the disease pro-
cess or a contributor to disease pathogenesis? Severe
phenotypes resulting from genetic loss of ether lipid pro-
duction suggest that these peroxisome-derived phospho-
lipids are responsible for fundamental cellular functions that
cannot be carried out by conventional phospholipids.
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Decreased ether lipid synthesis is linked to multiple neuro-
logical and metabolic abnormalities, while increased levels
are associated with cancer, suggesting that proper regula-
tion of ether lipid production is required for normal physiol-
ogy. Future research will be necessary to determine if
targeted inhibition of the ether lipid synthetic pathway could
treat malignancies. Conversely, there is a need to develop
novel dietary interventions to correct pathologies associated
with ether lipid deﬁciency. Several groups have attempted to
deliver alkylglycerols in diet to boost ether lipid levels in
deﬁcient animals with variable results. While the effects of
ether lipid replacement appear to be promising in peripheral
tissues, the results have been less successful in correcting
neurological deﬁcits (Brites et al., 2011; Rasmiena et al.,
2015; Jang et al., 2017). It will be of great interest to develop
more effective synthetic ether lipid precursors that could
cross the blood-brain barrier and alter the clinical course of
neurological diseases.
Currently there is a wide knowledge gap in our under-
standing of the molecular mechanisms underlying the
pathologies associated with altered production of these
lipids. Much work has been done using mouse models of
global ether lipid deﬁciency, revealing gross abnormalities
associated with such manipulations (da Silva et al., 2012).
Going forward it will be important to take a more ﬁne-tuned
approach through targeted inactivation of ether lipid pro-
duction to better deﬁne the biological roles of these unique
phospholipids, perhaps uncovering novel strategies for dis-
ease intervention.
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